Clinical Trials
48 trialsNCT02625480 2026-04-09
ZUMA-4
Gilead Sciences
Phase 1/2 Completed
NCT04673617 2026-04-03
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Artiva Biotherapeutics, Inc.
Phase 1/2 Completed
NCT02858310 2026-03-09
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04426669 2026-02-23
A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
Intima Bioscience, Inc.
Phase 1/2 Completed
NCT01203722 2026-02-19
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT06556108 2026-01-20
ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed
NCT02356159 2025-09-30
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04074746 2025-09-30
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02614066 2024-11-19
ZUMA-3
Gilead Sciences
Phase 1/2 Completed
NCT02400281 2024-07-03
Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT02348216 2024-06-04
ZUMA-1
Gilead Sciences
Phase 1/2 Completed
NCT03056339 2024-03-25
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02926833 2024-03-06
ZUMA-6
Gilead Sciences
Phase 1/2 Completed
NCT01904136 2024-01-24
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02626338 2023-12-20
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
Arog Pharmaceuticals, Inc.
Phase 1/2 Completed
NCT00047060 2023-11-14
Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924170 2023-11-14
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT04323657 2023-03-16
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
TCR2 Therapeutics
Phase 1/2 Completed
NCT03287674 2023-03-01
TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer
Herlev Hospital
Phase 1/2 Completed
NCT04030195 2023-01-31
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Precision BioSciences, Inc.
Phase 1/2 Completed
NCT02414945 2023-01-10
TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients
University Health Network, Toronto
Phase 1/2 Completed
NCT02111850 2022-03-29
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00924326 2022-01-12
CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00822770 2020-10-14
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02354690 2020-03-23
Vemurafenib and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT01289457 2020-02-24
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT02379195 2020-01-22
Peginterferon and TIL Therapy for Metastatic Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00048412 2020-01-18
Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H
Baylor College of Medicine
Phase 1/2 Completed
NCT01096992 2019-09-25
Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT03173417 2019-05-20
Safety and Efficacy Evaluation of IM19 CAR-T Cells (IM19CAR-T)
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 1/2 Completed
NCT00802113 2019-03-27
Autologous and Allogeneic Transplant for Relapsed Lymphoma
Columbia University
Phase 1/2 Completed
NCT00943319 2019-02-04
Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies
University of Chicago
Phase 1/2 Completed
NCT02280811 2017-09-06
T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01435343 2017-04-25
Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia
PETHEMA Foundation
Phase 1/2 Completed
NCT00536341 2017-01-16
Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
SCRI Development Innovations, LLC
Phase 1/2 Completed
NCT00429416 2016-11-29
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Thomas Jefferson University
Phase 1/2 Completed
NCT00937625 2015-08-18
T-cell Based Immunotherapy for of Melanoma
Herlev Hospital
Phase 1/2 Completed
NCT00809276 2015-02-16
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT00202917 2014-05-29
Haploidentical Transplantation With CD3/CD19 Depleted Grafts in Patients With Hematologic Malignancies
University Hospital Tuebingen
Phase 1/2 Completed
NCT00472849 2013-11-26
Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00738829 2013-08-30
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLL
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 1/2 Completed
NCT00048737 2013-06-13
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00038831 2012-08-01
Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00056966 2012-06-29
Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases
Baylor College of Medicine
Phase 1/2 Completed
NCT00253513 2012-06-01
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
OHSU Knight Cancer Institute
Phase 1/2 Completed
NCT00506857 2012-02-28
Phase I/II Trial of Fludarabine Plus Busulfan and Allogeneic Progenitor Cell Support
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00452374 2011-11-02
Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL
M.D. Anderson Cancer Center
Phase 1/2 Completed